Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—A 52-Week Analysis from a Phase 2 Study

Authors

A. B. Gottlieb, Icahn School of Medicine at Mt Sinai
C. T. Ritchlin, University of Rochester
R. C. Chou, University at Buffalo
A. M. Mendelsohn, Sun Pharmaceutical Industries, Inc
S. Rozzo, Sun Pharmaceutical Industries, Inc
L. Espinoza, LSU Health Sciences Center - New Orleans

Document Type

Article

Publication Date

6-13-2020

Publication Title

Annals of the Rheumatic Diseases

Volume

79(Suppl 1)

Comments

Abstract Number: SAT0417

Recommended Citation

Gottlieb, A. B.; Ritchlin, C. T.; Chou, R. C.; Mendelsohn, A. M.; Rozzo, S.; and Espinoza, L., "Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—A 52-Week Analysis from a Phase 2 Study" (2020). School of Medicine Faculty Publications. 1762.
https://digitalscholar.lsuhsc.edu/som_facpubs/1762
10.1136/annrheumdis-2020-eular.778